Conde
Showing 1–2 of 2 transcripts.
- a16z7 min
Pande & Conde on: Players and Paths for Healthcare Startups
The discussion outlines a strategic framework for healthcare startups, contrasting the lengthy regulatory paths of therapies and diagnostics with the rapid market entry offered by Laboratory-Developed Tests and R&D tool sales. Highlighting the $75 billion U.S. R&D market, the analysis features success stories like Atomab and Illumina to demonstrate how founders can leverage non-exclusive licensing models instead of pursuing costly end-user commercialization. Ultimately, the presentation advises entrepreneurs to align their go-to-market approach with specific proof points and regulatory requirements, choosing between partnership-based platforms and integrated drug development based on their technology's unique capabilities.
- a16z22 min
Pande & Conde: When (and How) Biology Becomes Engineering
The bioindustry is undergoing a fundamental shift from stochastic discovery to design-driven engineering by treating biological systems as modular, interchangeable components akin to mechanical parts. This paradigm leverages interdisciplinary convergence, mature technologies like CRISPR, and machine learning to transform drug development into a reproducible, iterative process where platform value compounds over time. Consequently, pharmaceutical companies are redefining themselves as data-generating entities that prioritize scalable, predictive systems over single asset creation to achieve complex, long-term health goals.